ADDITIONAL STUDIES

Sanofi has additional clinical trials for Praluent including:

ODYSSEY DM-Insulin [NCT02585778]1

A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of Praluent in insulin treated patients with type 1 or type 2 diabetes and with hypercholesterolemia at high cardiovascular risk not adequately controlled on maximally tolerated LDL-C lowering therapy.

For more information please see clinicaltrials.gov.

ODYSSEY DM -Dyslipidaemia [NCT02642159]2

A randomized, open-label, parallel group study to evaluate the efficacy and safety of Praluent versus usual care in patients with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk with non-HDL-C not adequately controlled with maximally tolerated statin therapy.

For more information on these trials and other trials involving Praluent please see clinicaltrials.gov.